NHS Expands SABR to 17,500 Prostate Cancer Patients Across 48 England Providers
Updated
Updated · Express · Jul 9
NHS Expands SABR to 17,500 Prostate Cancer Patients Across 48 England Providers
1 articles · Updated · Express · Jul 9
Summary
Around 17,500 men with low- or intermediate-risk prostate cancer will be offered SABR through 48 NHS providers in England, widening access beyond the specialist-centre trials where the treatment was previously limited.
SABR concentrates multiple radiation beams on the tumour and typically cuts treatment to about five doses instead of the usual 20, aiming to reduce damage to surrounding tissue and shorten recovery.
NHS modelling suggests about 1 in 5 eligible men will choose SABR, which is already used for some lung, pancreatic and liver cancers and is now being positioned as another option alongside surgery, focal therapy and active surveillance.
One trial patient, 70-year-old Edwin Lambert, said the sessions themselves were brief but side effects were intense and short-lived; his PSA has since fallen below 0.02 ng/mL in recovery.
Researchers are also testing whether SABR can help men with advanced prostate cancer, with Prostate Cancer UK investing £865,000 in the STAR-TRAP study to see if it can delay progression and postpone chemotherapy.
Clarkson chose HIFU, the NHS champions SABR. How can patients choose between these advanced prostate cancer treatments?
Will targeted screening for prostate cancer leave thousands of average-risk men to discover their disease too late?
As precision radiation becomes the new standard, what are the hidden long-term risks for prostate cancer survivors?
NHS England Expands SABR Access: Transforming Prostate Cancer Care with Shorter, Safer Radiotherapy
Overview
NHS England is expanding Stereotactic Ablative Radiotherapy (SABR) for men with early-stage, localised prostate cancer, aiming to make treatment more efficient and less demanding. Traditional radiotherapy often requires at least 15 to 20 sessions, creating significant challenges and travel time for patients and their families. In contrast, SABR delivers treatment in just five sessions over two weeks, dramatically reducing the burden. This condensed schedule is expected to improve patient experience by minimizing disruption to daily life, making cancer care less stressful and more accessible for thousands of men across the country.